Page 17 - Slide 1
P. 17

Amgen Bone Health Mentoring Program

            Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN

1065 LLP2A-Alendronate, a Novel Anabolic Treatment to

Reverse Bone Loss.

Yao W, Guan M, Jia J, et al.

Session: Concurrent Oral Session 11: Osteoporosis -
Treatment (Preclinical) ◼ Saturday , October 13, 03:15
PM - 03:30 PM ◼ Auditorium Room 3/Minneapolis

Convention Center

   Results                    Abstract Information           Additional Notes from
                                                              Poster/Presentation*
Conclusions   ▪ LLP2A-Ale partially prevented trabecular
Implications     bone loss induced by estrogen deficiency .  Updated/Additional
for Canadian                                                 Data, Key Takeaways
              ▪ MSC + LLP2A-Ale restored lost bone
   Practice      induced by estrogen deficiency through
                 increases in osteoblast surface and
                 mineral apposition rate.

              ▪ The effects of LLP2A-Ale + transplanted
                 MSCs were superior to LLP2A-Ale alone,
                 especially at the cortical bone

              ▪ As compared to placebo, BFR/BS was
                 increased by 35% in LLP2A-Ale group and
                 by 192% in MSC + LLP2A-Ale group.

              ▪ MSC +LLP2A-Ale treatment increased
                 cortical bone maximum stress by 8% as
                 compared to the placebo-treated group.

              ▪ LLP2A-Ale is a promising option for the
                 treatment of bone loss related to age and
                 hormone deficiency.

              Discussion Points, Key Takeaways
   12   13   14   15   16   17   18   19   20   21